cAMPNOMAD Cells are cell lines stably co-expressing tag-free GPCRs and cAMP Nomad Biosensor to monitor G-protein modulation by cAMP release. Each vial of cAMPNOMAD D1 Dopamine Receptor Cell Line contains HEK293 cells stably expressing the following constructs:
human D1 Dopamine Receptor (DRD1) with no tag
cAMP Nomad Biosensor (Red Fluorescence)
cAMPNOMAD DRD1 Cell Line allows to assay compounds analyzing the G-Protein signalling pathway by Gs involving receptor activation. When an agonist binds to DRD1, the Gs protein is activated which, in turn, triggers a cellular response mediated by cAMP via adenylate cyclase stimulation. This leads to an increase of red fluorescence intensity of cAMP biosensor. So, the activity can be easily quantified on living cells in a dose-response manner by fluorescence emission in a microplate reader.
cAMPNOMAD Cells are cell lines stably co-expressing tag-free GPCRs and cAMP Nomad Biosensor to monitor G-protein modulation by cAMP release. Each vial of cAMPNOMAD D2 Dopamine Receptor Cell Line contains U2OS cells stably expressing the following constructs:
human D2 Dopamine Receptor (DRD2) with no tag
cAMP Nomad Biosensor (Red Fluorescence)
cAMPNOMAD DRD2 Cell Line allows to assay compounds analyzing the G-Protein signalling pathway by Go involving receptor activation. When an agonist binds to DRD2, the Go protein is activated which, in turn, triggers a cellular response mediated by cAMP. This leads to an increase of red fluorescence intensity of cAMP biosensor. So, the activity can be easily quantified on living cells in a dose-response manner by fluorescence emission in a microplate reader.
cAMPNOMAD Cells are cell lines stably co-expressing tag-free GPCRs and cAMP Nomad Biosensor to monitor G-protein modulation by cAMP release. Each vial of cAMPNOMAD D5 Dopamine Receptor Cell Line contains U2OS cells stably expressing the following constructs:
human D5 Dopamine Receptor (DRD5) with no tag
cAMP Nomad Biosensor (Red Fluorescence)
cAMPNOMAD DRD5 Cell Line allows to assay compounds analyzing the G-Protein signalling pathway by Gs involving receptor activation. When an agonist binds to DRD5, the Gs protein is activated which, in turn, triggers a cellular response mediated by cAMP via adenylate cyclase stimulation. This leads to an increase of red fluorescence intensity of cAMP biosensor. So, the activity can be easily quantified on living cells in a dose-response manner by fluorescence emission in a microplate reader.
